Receive a weekly summary and discussion of the top papers of the week by leading researchers in the field.

In Reviews in cardiovascular medicine

Artificial Intelligence (AI), in general, refers to the machines (or computers) that mimic "cognitive" functions that we associate with our mind, such as "learning" and "solving problem". New biomarkers derived from medical imaging are being discovered and are then fused with non-imaging biomarkers (such as office, laboratory, physiological, genetic, epidemiological, and clinical-based biomarkers) in a big data framework, to develop AI systems. These systems can support risk prediction and monitoring. This perspective narrative shows the powerful methods of AI for tracking cardiovascular risks. We conclude that AI could potentially become an integral part of the COVID-19 disease management system. Countries, large and small, should join hands with the WHO in building biobanks for scientists around the world to build AI-based platforms for tracking the cardiovascular risk assessment during COVID-19 times and long-term follow-up of the survivors.

Suri Jasjit S, Puvvula Anudeep, Majhail Misha, Biswas Mainak, Jamthikar Ankush D, Saba Luca, Faa Gavino, Singh Inder M, Oberleitner Ronald, Turk Monika, Srivastava Saurabh, Chadha Paramjit S, Suri Harman S, Johri Amer M, Nambi Vijay, Sanches J Miguel, Khanna Narendra N, Viskovic Klaudija, Mavrogeni Sophie, Laird John R, Bit Arindam, Pareek Gyan, Miner Martin, Balestrieri Antonella, Sfikakis Petros P, Tsoulfas George, Protogerou Athanasios, Misra Durga Prasanna, Agarwal Vikas, Kitas George D, Kolluri Raghu, Teji Jagjit, Porcu Michele, Al-Maini Mustafa, Agbakoba Ann, Sockalingam Meyypan, Sexena Ajit, Nicolaides Andrew, Sharma Aditya, Rathore Vijay, Viswanathan Vijay, Naidu Subbaram, Bhatt Deepak L


COVID-19, artificial intelligence, cardiovascular, myocarditis, non-invasive monitoring, risk assessment